- Home
- AVT vs AKRO Comparison
AVT vs AKRO Comparison
Compare AVT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVT
- AKRO
- Stock Information
- Founded
- AVT 1921
- AKRO 2017
- Country
- AVT United States
- AKRO United States
- Employees
- AVT N/A
- AKRO N/A
- Industry
- AVT Electronic Components
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- AVT Technology
- AKRO Health Care
- Exchange
- AVT Nasdaq
- AKRO Nasdaq
- Market Cap
- AVT 4.3B
- AKRO 3.7B
- IPO Year
- AVT N/A
- AKRO 2019
- Fundamental
- Price
- AVT $50.64
- AKRO $53.90
- Analyst Decision
- AVT Sell
- AKRO Buy
- Analyst Count
- AVT 3
- AKRO 10
- Target Price
- AVT $49.00
- AKRO $73.56
- AVG Volume (30 Days)
- AVT 779.1K
- AKRO 4.1M
- Earning Date
- AVT 10-29-2025
- AKRO 11-07-2025
- Dividend Yield
- AVT 2.61%
- AKRO N/A
- EPS Growth
- AVT N/A
- AKRO N/A
- EPS
- AVT 2.75
- AKRO N/A
- Revenue
- AVT $22,200,754,000.00
- AKRO N/A
- Revenue This Year
- AVT $5.60
- AKRO N/A
- Revenue Next Year
- AVT $5.99
- AKRO N/A
- P/E Ratio
- AVT $18.38
- AKRO N/A
- Revenue Growth
- AVT N/A
- AKRO N/A
- 52 Week Low
- AVT $39.22
- AKRO $21.34
- 52 Week High
- AVT $59.24
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- AVT 42.86
- AKRO 68.71
- Support Level
- AVT $50.95
- AKRO $53.40
- Resistance Level
- AVT $52.81
- AKRO $54.05
- Average True Range (ATR)
- AVT 1.40
- AKRO 0.26
- MACD
- AVT -0.08
- AKRO -0.03
- Stochastic Oscillator
- AVT 58.53
- AKRO 72.46
About AVT Avnet Inc.
Avnet Inc is an electronic component technology distributor and solutions provider. It serves customers from startups and mid-sized businesses to enterprise-level original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and original design manufacturers (ODMs). The group operates in the Electronic Components segment and supports high and medium-volume customers to markets, sells, and distributes electronic components, and the Farnell segment supports lower-volume customers that need electronic components quickly to develop, prototype, and test their products. Its geographic regions are the Americas, EMEA, and Asia.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.